Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir

MT Newswires Live

04/27

Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.

It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.

It worked alongside Todd Strategy Group and MC2 to advance industry engagement initiatives in the US during the March quarter.

Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.

Its shares were up 1% in recent trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2630351272"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630351272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630351272?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630351272","market":"nz","top_or_hot":-1,"title":"Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a>' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.</p><p>It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.</p><p>It worked alongside Todd <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Group and MC2 to advance industry engagement initiatives in the US during the March quarter.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>Its shares were up 1% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsland Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-27 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a>' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.</p><p>It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.</p><p>It worked alongside Todd <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Group and MC2 to advance industry engagement initiatives in the US during the March quarter.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>Its shares were up 1% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2630351272","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630351272","pubTimestamp":1777266438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phas","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","ILA.AU":"ISLAND PHARMACEUTICALS LTD"},"translate_title":"Island Pharmaceuticals与USAMRIID合作推进加利德西韦的临床开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILA.AU":1},"content_text":"Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.It worked alongside Todd Strategy Group and MC2 to advance industry engagement initiatives in the US during the March quarter.Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.Its shares were up 1% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}